Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Source: globenewswire.com
Immunogenicity Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Immunogenicity Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Immunogenicity Data Today - Breaking & Trending Today
Pfizer study on COVID vaccine safety included only 23 people
The Food and Drug Administration is charged with making sure products, including medicines, delivered to American consumers have been tested for safety.
Source: wnd.com
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023
Source: marketscreener.com
Advaxis Reports Second Quarter Ended April 30, 2022
Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...
Source: globenewswire.com
Advaxis to Present Updated Clinical and Immunogenicity Data
Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...
Source: globenewswire.com